Fluvastatin

How to order Fluvastatin

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Fluvastatin on Prescriptsy

Fluvastatin is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Fluvastatin is a prescription-only statin medicine used to lower cholesterol and reduce the risk of cardiovascular disease.

It belongs to the HMG-CoA reductase inhibitor class and is available as 20 mg and 40 mg immediate-release capsules and 80 mg modified-release (XL) tablets.

Fluvastatin is available in the UK as a generic medicine and under the brand name Lescol.

It is used alongside dietary and lifestyle modifications to treat primary hypercholesterolaemia (high LDL cholesterol) and mixed dyslipidaemia (elevation of both LDL cholesterol and triglycerides), and for secondary prevention of major cardiovascular events following percutaneous coronary intervention.

Cardiovascular disease (CVD) remains the leading cause of death worldwide and the second most common cause of death in the United Kingdom, accounting for approximately 160,000 deaths per year.

High blood cholesterol, particularly elevated low-density lipoprotein (LDL) cholesterol, is one of the most important modifiable risk factors for atherosclerotic CVD.

LDL cholesterol deposits in the walls of arteries contribute to the formation of atherosclerotic plaques, which can narrow arteries (causing angina and peripheral arterial disease) or rupture (causing heart attack and stroke).

Statins are the most widely prescribed class of cholesterol-lowering drugs and have the strongest evidence base for reducing cardiovascular events and mortality.

This page provides a comprehensive clinical overview of fluvastatin, including its mechanism of action, dosing, side effects, safety warnings, and how to obtain a prescription in the UK.

Important safety information about fluvastatin

• Fluvastatin is a prescription-only medicine (POM) and should be taken as directed by your prescriber.
• Report unexplained muscle pain, tenderness, or weakness to your GP immediately, especially if accompanied by fever or dark urine.
• Fluvastatin is contraindicated in pregnancy and breastfeeding.
• Liver function tests should be performed before starting treatment.
• Fluvastatin should be used alongside dietary and lifestyle changes, not as a substitute for them.

Understanding cholesterol and cardiovascular risk

Cholesterol is a waxy substance produced by the liver and also obtained from dietary sources.

It is essential for building cell membranes, producing hormones (including oestrogen, testosterone, and cortisol), and synthesising vitamin D. Cholesterol travels in the bloodstream attached to proteins, forming lipoproteins.

LDL cholesterol carries cholesterol from the liver to the tissues and is considered "bad" cholesterol because excess LDL deposits in artery walls, contributing to atherosclerosis.

HDL cholesterol carries cholesterol away from the arteries back to the liver for disposal and is considered "good" cholesterol.

Triglycerides are another type of blood fat that contribute to cardiovascular risk when elevated.

NICE guideline CG181 (cardiovascular disease: risk assessment and reduction, including lipid modification) recommends assessing 10-year cardiovascular risk using the QRISK3 calculator for all adults over 40 without pre-existing CVD.

Statin therapy is recommended for primary prevention when the 10-year CVD risk is 10% or greater, and for all patients with established CVD (secondary prevention).

The target for secondary prevention is a greater than 40% reduction in non-HDL cholesterol from the pre-treatment level.

How fluvastatin works: mechanism of action

All statins work by inhibiting HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for hepatic cholesterol biosynthesis.

When cholesterol synthesis in the liver is reduced, hepatocytes respond by upregulating the expression of LDL receptors on their cell surface.

These receptors bind and remove LDL particles from the bloodstream, thereby lowering circulating LDL cholesterol levels.

Statins also reduce VLDL production by the liver, contributing to a modest reduction in triglycerides, and raise HDL cholesterol levels by a small amount (typically 5 to 10%).

Beyond lipid lowering, statins exert pleiotropic (additional beneficial) effects that contribute to cardiovascular protection independently of cholesterol reduction.

These include improvement of endothelial function (the ability of blood vessel walls to dilate), reduction of vascular inflammation (lowering C-reactive protein levels), stabilisation of atherosclerotic plaques (making them less likely to rupture and cause heart attacks), inhibition of platelet aggregation, and anti-thrombotic effects.

Fluvastatin is distinguished from other statins by its primary metabolism through CYP2C9 rather than CYP3A4.

This is clinically significant because CYP3A4 is the enzyme inhibited by a wide range of commonly prescribed drugs (macrolide antibiotics, azole antifungals, HIV protease inhibitors, calcium channel blockers, grapefruit juice).

Statin-related myopathy risk increases when statin plasma levels rise due to CYP3A4 inhibition, so fluvastatin carries a lower interaction risk in patients taking multiple medications.

Clinical evidence supporting fluvastatin

The LIPS (Lescol Intervention Prevention Study) trial demonstrated that fluvastatin 80 mg daily in patients who had undergone their first successful percutaneous coronary intervention reduced the risk of major adverse cardiac events (cardiac death, non-fatal MI, recoronary intervention) by 22% compared with placebo over a median follow-up of 3.9 years.

This established fluvastatin's role in secondary prevention after coronary revascularisation.

The statin class as a whole has an enormous evidence base from landmark trials (4S, WOSCOPS, CARE, LIPID, HPS, CARDS, JUPITER, ASCOT-LLA) demonstrating consistent reductions in cardiovascular events and mortality across diverse patient populations.

Meta-analyses from the Cholesterol Treatment Trialists' (CTT) Collaboration show that each 1 mmol/L reduction in LDL cholesterol reduces the risk of major vascular events by approximately 22% and coronary events by 24%.

While most of this evidence was generated with simvastatin, atorvastatin, pravastatin, and rosuvastatin, the effect is considered a class effect driven primarily by the degree of LDL lowering achieved.

Fluvastatin is a less potent statin, achieving LDL reductions of approximately 20 to 25% at 40 mg daily and 30 to 35% at 80 mg daily (modified-release).

It is therefore most appropriate for patients who require moderate cholesterol lowering, who need a statin with fewer CYP3A4-mediated drug interactions, or who have not tolerated more potent statins.

UK prescribing guidance for fluvastatin

NICE CG181 recommends atorvastatin 20 mg as the first-line statin for primary prevention and atorvastatin 80 mg for secondary prevention.

However, if atorvastatin is not tolerated (most commonly due to muscle side effects), alternative statins including fluvastatin may be used.

The BNF lists fluvastatin as an option for hypercholesterolaemia and for secondary prevention following PCI.

Prescribers should aim for the LDL or non-HDL cholesterol targets recommended by NICE and adjust the statin choice and dose accordingly.

In clinical practice, fluvastatin is most commonly considered as a second- or third-line statin when atorvastatin (first choice) and rosuvastatin (common second choice) have caused intolerable myalgia.

Its lower potency means it achieves smaller absolute reductions in LDL, but for some patients, a moderate reduction with good tolerability is preferable to a larger reduction with debilitating muscle pain.

Pravastatin is another less potent option with minimal CYP450 metabolism.

Fluvastatin compared with other statins

The statins available in the UK can be ranked by potency (LDL-lowering capacity): rosuvastatin is the most potent, followed by atorvastatin, simvastatin, fluvastatin, and pravastatin.

At maximum recommended doses, rosuvastatin 40 mg reduces LDL by approximately 55%, atorvastatin 80 mg by 50%, simvastatin 80 mg by 42% (though the 80 mg dose is rarely used due to myopathy risk), fluvastatin 80 mg by 33%, and pravastatin 40 mg by 30%.

The key pharmacokinetic advantage of fluvastatin is its CYP2C9 metabolism, which reduces the risk of drug interactions with CYP3A4 inhibitors.

This makes fluvastatin a potentially safer choice for patients taking erythromycin, clarithromycin, ketoconazole, itraconazole, verapamil, diltiazem, ciclosporin, or HIV protease inhibitors.

Pravastatin shares this advantage, as it is minimally metabolised by CYP enzymes.

The choice between fluvastatin and pravastatin depends on the degree of LDL reduction required and individual patient factors.

Dosage and administration

Immediate-release capsules (20 mg or 40 mg) should be taken in the evening, as hepatic cholesterol synthesis peaks during the night.

They may be swallowed whole with water, with or without food.

The modified-release tablet (80 mg) may be taken at any time of day due to its sustained-release profile and should be swallowed whole without crushing or chewing.

The usual starting dose for primary hypercholesterolaemia is 20 to 40 mg daily.

If further LDL reduction is needed, the dose may be increased to 40 mg twice daily or 80 mg once daily (modified-release).

For secondary prevention after PCI, 80 mg once daily (modified-release) is the recommended dose.

Lipid levels should be rechecked after 4 to 6 weeks and the dose adjusted accordingly. The maximum daily dose is 80 mg.

Side effects of fluvastatin

Common side effects

Headache, dyspepsia, nausea, abdominal pain, and insomnia are the most frequently reported.

Myalgia (muscle pain without CK elevation) affects a small proportion of patients and is the most common reason for statin discontinuation or switching.

Elevated liver transaminases (ALT, AST) may occur and are usually asymptomatic and reversible.

Uncommon and rare side effects

Myopathy (CK above 10 times ULN with symptoms) and rhabdomyolysis are uncommon and rare respectively. The risk is lower with fluvastatin than with simvastatin or atorvastatin.

Peripheral neuropathy (numbness, tingling, weakness in hands and feet) and memory disturbances have been reported rarely and are usually reversible.

New-onset type 2 diabetes has been associated with statin therapy as a class; the risk is small and is outweighed by cardiovascular benefits in indicated patients.

Immune-mediated necrotising myopathy (IMNM) is an extremely rare condition requiring immunosuppressive treatment. Interstitial lung disease is very rare.

When to seek urgent help

Stop fluvastatin and call your GP urgently if you develop unexplained muscle pain, tenderness, or weakness, especially if accompanied by dark (cola-coloured) urine, fever, or malaise.

These may be signs of serious muscle damage.

Call 999 or go to A&E if you develop signs of a severe allergic reaction (facial swelling, breathing difficulty) or signs of liver failure (jaundice, severe abdominal pain, confusion).

Call NHS 111 for persistent gastrointestinal symptoms, troublesome muscle aching without danger signs, or other concerns about side effects.

Report suspected adverse reactions via the Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Liver monitoring

Liver function tests should be performed before initiating fluvastatin. Monitor again if signs or symptoms of hepatotoxicity develop.

If transaminases exceed 3 times the upper limit of normal persistently, discontinue treatment. Fluvastatin is contraindicated in active liver disease or unexplained persistent transaminase elevation.

Muscle monitoring

Check baseline CK in patients at high risk of myopathy before starting treatment. Measure CK promptly if muscle symptoms develop during treatment.

Discontinue if CK exceeds 10 times ULN, or consider stopping if CK is 5 to 10 times ULN with symptoms.

Risk factors for statin myopathy include high statin dose, advanced age, female sex, low body weight, hypothyroidism, renal impairment, genetic predisposition, and concomitant interacting drugs.

Drug interactions

Fluvastatin is metabolised by CYP2C9. Inhibitors of CYP2C9 (fluconazole, amiodarone, voriconazole) increase fluvastatin exposure. Monitor for muscle symptoms and consider dose reduction.

Gemfibrozil increases the risk of myopathy when combined with any statin; if a fibrate is needed, fenofibrate is the preferred choice.

Ciclosporin increases statin exposure; use the lowest effective statin dose with close monitoring. Fluvastatin may enhance the effect of warfarin; check INR on initiation and dose changes.

Bile acid sequestrants reduce fluvastatin absorption; separate dosing by at least 4 hours. Colchicine may increase the risk of myopathy and should be combined with caution.

Pregnancy and breastfeeding

Fluvastatin is contraindicated in pregnancy and breastfeeding. Cholesterol and its intermediates are vital for normal foetal development. Women of childbearing potential must use effective contraception throughout treatment.

If pregnancy is discovered, stop fluvastatin immediately. Fluvastatin passes into breast milk and must not be taken while breastfeeding.

Diabetes risk

Statins as a class are associated with a small increase in the risk of developing type 2 diabetes, particularly at higher doses and in patients with pre-existing risk factors for diabetes (obesity, impaired fasting glucose, metabolic syndrome).

However, the cardiovascular benefits of statin therapy substantially outweigh this risk. Patients should be monitored for new-onset diabetes during statin treatment.

How to get fluvastatin in the UK

Fluvastatin is a prescription-only medicine available on the NHS.

Your GP can prescribe it following a cardiovascular risk assessment and blood tests (fasting lipid profile, liver function tests, and potentially thyroid and renal function).

Authorised online prescribers registered with the General Pharmaceutical Council (GPhC) can also prescribe fluvastatin after an appropriate clinical consultation.

The NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Generic fluvastatin capsules and modified-release tablets are widely available at low cost.

Living with high cholesterol: lifestyle alongside fluvastatin

Statin therapy is most effective when combined with heart-healthy lifestyle changes.

NICE recommends reducing dietary saturated fat and replacing it with unsaturated fats, eating more fruit, vegetables, wholegrains, oily fish, and foods rich in soluble fibre (oats, beans, lentils, and pulses).

Maintaining a healthy weight, exercising for at least 150 minutes per week at moderate intensity, stopping smoking, and limiting alcohol intake all contribute to reducing cardiovascular risk.

Home cholesterol testing is not routinely recommended; instead, your GP surgery will arrange periodic blood tests to monitor your lipid levels and response to treatment.

If your cholesterol targets are not achieved with fluvastatin at maximum dose, your prescriber may switch you to a more potent statin (atorvastatin or rosuvastatin) or, in selected high-risk patients, add ezetimibe or refer for consideration of PCSK9 inhibitor therapy.

Sources

• Fluvastatin 40 mg Capsules, Summary of Product Characteristics (EMC)
• Fluvastatin, British National Formulary (BNF)
• NICE CG181: Cardiovascular disease: risk assessment and reduction, including lipid modification
• High cholesterol, NHS
• MHRA Yellow Card Scheme